Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,085 total articles

Grocery Outlet Holding Corp. Adds Two New Independent Directors

Grocery Outlet Holding Corp. Adds Two New Independent Directors

Grocery Outlet Holding Corp., a U.S.-based extreme value retailer, announced the appointment of Frances Allen and Felicia Thornton to its Board of Directors to enhance expertise aligned with strategic priorities. Both bring extensive experience in grocery and retail sectors, brand strategy, marketing, finance, and operations. These strategic additi…

Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

Relay Therapeutics announced it will present initial clinical and preclinical data on its lead drug candidate, zovegalisib, a mutant-selective PI3Kα inhibitor, in PIK3CA-driven vascular anomalies at the ISSVA World Congress 2026. Zovegalisib is also in advanced development for HR+/HER2- metastatic breast cancer and aims to address a large patient p…

Oportun Provides Updates on Leadership Transition

Oportun Provides Updates on Leadership Transition

Oportun Financial Corporation announced that Kate Layton and Gaurav Rana will serve as interim co-CEOs following the departure of CEO Raul Vazquez. Both executives will retain their current roles while leading the company during the CEO search. Vazquez will continue as an advisor until July 2026 to facilitate a smooth transition. The board is activ…

Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares

Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares

Safe Bulkers, Inc., a marine drybulk transportation services provider, announced quarterly cash dividends of $0.50 per share on its 8.00% Series C and Series D Cumulative Redeemable Perpetual Preferred Shares, payable on April 30, 2026. Future dividends remain at the discretion of the Board of Directors, depending on company performance and financi…

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Adagene Inc., a clinical-stage biotech company specializing in novel antibody-based cancer immunotherapies, announced the pricing of an underwritten public offering of 18.67 million ADSs at $3.75 each, raising gross proceeds of approximately $70 million. The offering attracted participation from both new and existing institutional investors and is …

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics announced inducement stock option grants to two new employees, totaling 52,450 shares at an exercise price of $6.39 per share. The options vest over four years with a ten-year term, granted to attract talent under Nasdaq inducement rules. Cartesian is advancing its lead CAR-T therapy, Descartes-08, in clinical trials for auto…

HMH Holding Inc. Announces Closing of Initial Public Offering

HMH Holding Inc. Announces Closing of Initial Public Offering

HMH Holding Inc., a provider of mission-critical drilling equipment and services for oil and gas operations, completed its initial public offering of 10.52 million Class A shares at $20.00 each, raising net proceeds of about $193.8 million. The shares commenced trading on The Nasdaq Global Select Market on April 1, 2026, under the symbol 'HMH'. The…

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Bio announced it received a U.S. patent covering the use of its investigational drug buntanetap in preventing and treating neurological injuries caused by brain infections, including those linked to Alzheimer's disease. The patent extends through 2044 and covers both preventive and therapeutic applications against a range of infectious agen…

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a reimbursement coverage agreement with Highmark for its CNSide CSF Tumor Cell Enumeration assay, increasing total covered lives from approximately 67 million to 75 million. This expands patient access and supports broader adoption of CNSide in the detection and monitoring of met…

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics announced that the FDA has granted Fast Track Designation to its investigational drug CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, aimed at treating platinum-resistant ovarian cancer. The company is conducting a Phase 1 clinical trial with interim data expected in June 2026. This designation could expedite the de…

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

MiNK Therapeutics disclosed that its investigational allogeneic iNKT cell therapy, agenT-797, will be featured at the ASGCT 2026 meeting. The therapy harnesses innate and adaptive immunity to target cancer, immune-mediated diseases, and severe pulmonary inflammation. The presentation underscores agenT-797's potential to modulate adaptive immune res…

FibroBiologics Announces Closing of $3 Million Public Offering

FibroBiologics Announces Closing of $3 Million Public Offering

FibroBiologics, a clinical-stage biotech company specializing in fibroblast-based therapeutics, closed a best efforts public offering raising approximately $3 million before fees. The offering included common stock and warrants exercisable upon stockholder approval, with potential additional proceeds of $3 million if warrants are exercised. Proceed…

CN Reports March Grain Movement

CN Reports March Grain Movement

CN reported moving over 2.96 million metric tonnes of grain from Western Canada in March 2026, setting a new record for the month and achieving the highest first quarter grain movement results ever. Despite late-month weather disruptions affecting terminal capacity, CN quickly restored network performance, supported by a strong export demand and th…

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Esperion Therapeutics has finalized the acquisition of Corstasis Therapeutics, incorporating the FDA-approved Enbumyst nasal spray loop diuretic into its cardiovascular portfolio. This addition expands Esperion's treatment offerings for edema related to congestive heart failure and other conditions, enhancing outpatient care options and supporting …

Century Aluminum Applauds President Trump for Executive Order to Fully Enforce Sec. 232 Aluminum Tariffs

Century Aluminum Applauds President Trump for Executive Order to Fully Enforce Sec. 232 Aluminum Tariffs

Century Aluminum applauds President Trump's executive order to enforce Section 232 aluminum tariffs fully by closing valuation loopholes that importers exploited to reduce tariff payments. The 50% tariffs remain unchanged, and the order requires importers to declare the full value of aluminum products, supporting fair competition and benefiting dom…